Semaglutide's Effects on Obstructive Sleep Apnea in T2DM/Obesity Patients Investigated in Real-World Study

Obstructive Sleep Apnea (OSA) is a highly prevalent and serious sleep disorder characterized by recurrent episodes of upper airway collapse during sleep, leading to intermittent hypoxia and sleep fragmentation. It frequently coexists with Type 2 Diabetes Mellitus (T2DM) and obesity, exacerbating metabolic dysfunction and increasing cardiovascular risk. Semaglutide, a potent GLP-1 receptor agonist, is a well-established treatment for T2DM and obesity, demonstrating significant benefits in glycemic control and weight reduction. However, despite its metabolic improvements, the direct effect of semaglutide on the underlying pathophysiology or severity of OSA, specifically measured by the Apnea-Hypopnea Index (AHI), remains an important clinical question. Current management strategies for OSA primarily involve continuous positive airway pressure (CPAP) therapy or surgical interventions, with limited pharmacological options directly targeting the condition itself, highlighting a significant therapeutic gap.

This single-center, real-world study (RWS) was designed to evaluate the impact of semaglutide treatment on 15 patients diagnosed with Type 2 Diabetes Mellitus (T2DM), obesity, and comorbid Obstructive Sleep Apnea (OSA). The study protocol involved assessing changes in various parameters after both 1-week and 4-week treatment durations. The primary efficacy endpoint was the Apnea-Hypopnea Index (AHI), a key measure of OSA severity. Secondary outcomes included comprehensive metabolic profiling, such as body weight, BMI, blood pressure, fasting blood glucose, glycated albumin, liver function tests, blood lipids, and waist circumference. This design aimed to provide initial real-world evidence on semaglutide's potential utility in the broader management of OSA within this specific patient cohort.